| 11.99 -0.45 (-3.62%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.28 | 1-year : | 16.51 |
| Resists | First : | 13.08 | Second : | 14.14 |
| Pivot price | 12.77  |
|||
| Supports | First : | 11.38 | Second : | 9.46 |
| MAs | MA(5) : | 11.86 |
MA(20) : | 12.88 |
| MA(100) : | 11.42 |
MA(250) : | 9.53 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 25.4 |
D(3) : | 17.8 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 18.93 | Low : | 5.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARVN ] has closed above bottom band by 25.3%. Bollinger Bands are 52.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.49 - 12.56 | 12.56 - 12.62 |
| Low: | 11.69 - 11.77 | 11.77 - 11.83 |
| Close: | 11.88 - 12 | 12 - 12.11 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Sat, 21 Feb 2026
Arvinas, Inc. $ARVN Position Trimmed by Monaco Asset Management SAM - MarketBeat
Fri, 20 Feb 2026
Arvinas, Inc. (ARVN) Stock Analysis: Unlocking Potential in Biotechnology with an 8.52% Upside - DirectorsTalk Interviews
Wed, 18 Feb 2026
Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,016 Shares - MarketBeat
Wed, 18 Feb 2026
Arvinas (NASDAQ:ARVN) CFO Sells $61,043.26 in Stock - MarketBeat
Wed, 18 Feb 2026
Insider Selling: Arvinas (NASDAQ:ARVN) Insider Sells 5,685 Shares of Stock - MarketBeat
Wed, 18 Feb 2026
Arvinas’ (ARVN) chief medical officer Berkowitz sells $67,594 in stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 93.9 (%) |
| Shares Short | 5,050 (K) |
| Shares Short P.Month | 6,740 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.96 |
| Profit Margin | -18.8 % |
| Operating Margin | -105.1 % |
| Return on Assets (ttm) | -6.4 % |
| Return on Equity (ttm) | -10.2 % |
| Qtrly Rev. Growth | -59.1 % |
| Gross Profit (p.s.) | 4.86 |
| Sales Per Share | 4.86 |
| EBITDA (p.s.) | -1.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -328 (M) |
| Levered Free Cash Flow | -135 (M) |
| PE Ratio | -14.81 |
| PEG Ratio | 0 |
| Price to Book value | 1.5 |
| Price to Sales | 2.46 |
| Price to Cash Flow | -2.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|